Cargando…
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452134/ https://www.ncbi.nlm.nih.gov/pubmed/34555502 http://dx.doi.org/10.1016/j.annonc.2021.09.009 |
| _version_ | 1784570006165520384 |
|---|---|
| author | Nelli, F. Fabbri, A. Onorato, A. Giannarelli, D. Silvestri, M.A. Giron Berrios, J.R. Virtuoso, A. Marrucci, E. Signorelli, C. Chilelli, M.G. Primi, F. Schirripa, M. Mazzotta, M. Ruggeri, E.M. |
| author_facet | Nelli, F. Fabbri, A. Onorato, A. Giannarelli, D. Silvestri, M.A. Giron Berrios, J.R. Virtuoso, A. Marrucci, E. Signorelli, C. Chilelli, M.G. Primi, F. Schirripa, M. Mazzotta, M. Ruggeri, E.M. |
| author_sort | Nelli, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8452134 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84521342021-09-21 Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study Nelli, F. Fabbri, A. Onorato, A. Giannarelli, D. Silvestri, M.A. Giron Berrios, J.R. Virtuoso, A. Marrucci, E. Signorelli, C. Chilelli, M.G. Primi, F. Schirripa, M. Mazzotta, M. Ruggeri, E.M. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2022-01 2021-09-20 /pmc/articles/PMC8452134/ /pubmed/34555502 http://dx.doi.org/10.1016/j.annonc.2021.09.009 Text en © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Nelli, F. Fabbri, A. Onorato, A. Giannarelli, D. Silvestri, M.A. Giron Berrios, J.R. Virtuoso, A. Marrucci, E. Signorelli, C. Chilelli, M.G. Primi, F. Schirripa, M. Mazzotta, M. Ruggeri, E.M. Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| title | Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| title_full | Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| title_fullStr | Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| title_full_unstemmed | Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| title_short | Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study |
| title_sort | effects of active cancer treatment on safety and immunogenicity of covid-19 mrna-bnt162b2 vaccine: preliminary results from the prospective observational vax-on study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452134/ https://www.ncbi.nlm.nih.gov/pubmed/34555502 http://dx.doi.org/10.1016/j.annonc.2021.09.009 |
| work_keys_str_mv | AT nellif effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT fabbria effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT onoratoa effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT giannarellid effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT silvestrima effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT gironberriosjr effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT virtuosoa effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT marruccie effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT signorellic effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT chilellimg effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT primif effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT schirripam effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT mazzottam effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy AT ruggeriem effectsofactivecancertreatmentonsafetyandimmunogenicityofcovid19mrnabnt162b2vaccinepreliminaryresultsfromtheprospectiveobservationalvaxonstudy |